Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)

Executive Summary

• Health Canada has accepted Cipher Pharmaceuticals’ new drug submission (NDS) for Natroba™ (Spinosad) for review, moving the product one step closer to potential Canadian market approval.
• If approved, Cipher plans to commercialize Natroba™ directly through its existing Canadian sales and distribution network, addressing an unmet need for head‑lice and scabies treatment in Canada.
• The announcement follows Cipher’s July 2024 acquisition of Natroba™, which is already marketed in the United States and recognized as a highly effective single‑dose therapy.

Key Details

• Regulatory Milestone: Health Canada accepted the NDS on Jan 28, 2026; review timeline not disclosed.
• Product Overview: Natroba™ (Spinosad) treats head lice and scabies with a single application; superior to permethrin 1% in the U.S. and meets FDA “complete cure” criteria for scabies.
• Acquisition Background: Cipher acquired Natroba™ in July 2024 and has been marketing it in the United States since then.
• Commercial Strategy (if approved): Direct commercialization in Canada via Cipher’s existing sales and distribution infrastructure.
• Market Need: Current Canadian head‑lice products face resistance issues; Natroba™ offers a proven, single‑treatment solution for both lice and scabies.
• Executive Comment: Interim CEO Craig Mull stated the acceptance “puts us one step closer to providing Canadians with an effective single treatment option,” reflecting the company’s strategic objective post‑acquisition.

Notable Quotes

“Health Canada's acceptance of our NDS and commitment to review puts us one step closer to providing Canadians with an effective single treatment option for head lice and scabies, which is an objective we had established upon acquiring the product.” – Craig Mull, Interim CEO, Cipher Pharmaceuticals.